| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
CID91585 (EM-12) is a thalidomide analog with teratogenic activity. While the precise molecular target is not fully defined, thalidomide and its analogs are known to interact with the CRBN (cereblon) E3 ubiquitin ligase complex, affecting the ubiquitination and degradation of various substrate proteins.
|
|---|---|
| ln Vitro |
In vitro, CID91585 exhibits teratogenic activity in cell-based models. As a thalidomide analog, it is expected to modulate CRBN-dependent protein degradation pathways. EM-12 is reported to be more active and hydrolytically stable than thalidomide, suggesting enhanced in vitro potency.
|
| ln Vivo |
In vivo, CID91585 (150 mg/kg, intravenous administration) induces fetal resorption and skeletal malformation in surviving offspring in rats, rabbits, and rhesus monkeys. It also enhances 1,2-dimethylhydrazine-induced colon adenocarcinoma formation in rats. These effects highlight its potent biological activity and teratogenic potential.
|
| Enzyme Assay |
The binding of CID91585 to its target proteins (such as CRBN) is typically assessed using surface plasmon resonance (SPR) or fluorescence polarization assays. Competition binding experiments with fluorescently labeled thalidomide analogs can be used to determine the compound's affinity for the CRBN-DDB1 complex.
|
| Cell Assay |
In vitro cellular assays for CID91585 involve treating cells with the compound and assessing CRBN-dependent protein degradation. Target protein levels (e.g., IKZF1, IKZF3) are measured by Western blotting. Cell viability and proliferation assays are performed to evaluate the compound's cytotoxic effects. Teratogenicity is assessed using embryonic stem cell differentiation models.
|
| Animal Protocol |
In vivo studies of CID91585 are conducted in pregnant animal models (rats, rabbits, and rhesus monkeys) to assess teratogenic effects. The compound is administered intravenously at doses such as 150 mg/kg. Fetal resorption and skeletal malformations in offspring are evaluated. Colon cancer induction studies are performed in rats using 1,2-dimethylhydrazine co-administration.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CID91585 (molecular weight 244.25) are evaluated in rodents following administration. The compound's enhanced hydrolytic stability compared to thalidomide suggests improved metabolic stability. Plasma concentrations are measured using HPLC or LC-MS/MS to determine PK parameters.
|
| Toxicity/Toxicokinetics |
CID91585 (EM-12) exhibits teratogenic activity and is classified as a hazardous compound. It is intended for research use only and is not approved for human therapeutic use. The compound's teratogenic potential necessitates careful handling and appropriate safety precautions in laboratory settings.
|
| Additional Infomation |
Em-12 is a white crystalline powder. (NTP, 1992)
CID91585 is a research tool for studying the teratogenic mechanisms of thalidomide analogs. Thalidomide and its derivatives are known to cause severe birth defects through their interaction with CRBN, which alters the degradation of transcription factors essential for limb development. EM-12 serves as a valuable analog for understanding the structure-activity relationships and mechanisms of thalidomide teratogenicity. |
| Molecular Formula |
C13H12N2O3
|
|---|---|
| Molecular Weight |
244.25
|
| Exact Mass |
244.085
|
| Elemental Analysis |
C, 63.93; H, 4.95; N, 11.47; O, 19.65
|
| CAS # |
26581-81-7
|
| Related CAS # |
26581-81-7;
|
| PubChem CID |
91585
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.393g/cm3
|
| Boiling Point |
534.3ºC at 760mmHg
|
| Melting Point |
460 to 464 °F (NTP, 1992)
|
| Flash Point |
276.9ºC
|
| LogP |
0.661
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
407
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1CCC(N2CC3=CC=CC=C3C2=O)C(=O)N1
|
| InChi Key |
WENKGSGGXGQHSH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H12N2O3/c16-11-6-5-10(12(17)14-11)15-7-8-3-1-2-4-9(8)13(15)18/h1-4,10H,5-7H2,(H,14,16,17)
|
| Chemical Name |
3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
| Synonyms |
CID 91585; CID-91585; CID91585; EM12; α-EM 12;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~511.77 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0942 mL | 20.4708 mL | 40.9417 mL | |
| 5 mM | 0.8188 mL | 4.0942 mL | 8.1883 mL | |
| 10 mM | 0.4094 mL | 2.0471 mL | 4.0942 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
